We studied the mechanisms underlying the important role of TGFβ signalling in T H 17 cell differentiation [6][7] [8] [9] [10] . We found that CD4 + T cells from wild-type and Cd4-cre;Smad4 fl/fl (S4 knockout) mice 11 differentiated into T H 17 cells comparably in the presence of interleukin (IL)-6 and TGFβ , as reported previously 12 . However, in stark contrast to wildtype T cells, SMAD4-deficient T cells consistently differentiated into T H 17 cells when provided with IL-6 alone without TGFβ (Fig. 1a) . This observation prompted us to hypothesize that SMAD4 deletion may result in T H 17 cell differentiation in the absence of TGFβ signalling. To test this hypothesis, we blocked TGFβ signalling by using a pharmacological inhibitor of TGFβ receptor ( TGFβ R) kinase activity. Whereas wild-type T cells did not become T H 17 cells, SMAD4-deficient T cells readily differentiated into T H 17 cells and expressed T H 17-related genes when TGFβ signalling was inhibited (Fig. 1a, b and Extended Data  Fig. 1a) . To confirm this finding and exclude the potential off-target effect of the inhibitor, we generated Cd4-cre;Smad4 fl/fl ;Tgfbr2 fl/fl (S4-RII double-knockout) mice, in which both SMAD4 and TGFβ receptor II (TGFβ RII) were deleted specifically in T cells 11,[13][14][15] . In agreement with the results of the experiments using the TGFβ R inhibitor, S4-RII double-knockout CD4
. We found that CD4 + T cells from wild-type and Cd4-cre;Smad4 fl/fl (S4 knockout) mice 11 differentiated into T H 17 cells comparably in the presence of interleukin (IL)-6 and TGFβ , as reported previously 12 . However, in stark contrast to wildtype T cells, SMAD4-deficient T cells consistently differentiated into T H 17 cells when provided with IL-6 alone without TGFβ (Fig. 1a) . This observation prompted us to hypothesize that SMAD4 deletion may result in T H 17 cell differentiation in the absence of TGFβ signalling. To test this hypothesis, we blocked TGFβ signalling by using a pharmacological inhibitor of TGFβ receptor ( TGFβ R) kinase activity. Whereas wild-type T cells did not become T H 17 cells, SMAD4-deficient T cells readily differentiated into T H 17 cells and expressed T H 17-related genes when TGFβ signalling was inhibited (Fig. 1a, b and Extended Data Fig. 1a ). To confirm this finding and exclude the potential off-target effect of the inhibitor, we generated Cd4-cre;Smad4 fl/fl ;Tgfbr2 fl/fl (S4-RII double-knockout) mice, in which both SMAD4 and TGFβ receptor II (TGFβ RII) were deleted specifically in T cells 11, [13] [14] [15] . In agreement with the results of the experiments using the TGFβ R inhibitor, S4-RII double-knockout CD4
+ T cells differentiated into T H 17 cells when only IL-6 was provided (Fig. 1c, d) .
Intrigued by the findings obtained in vitro, we further investigated whether SMAD4-deficient T cells could differentiate into T H 17 cells in the absence of TGFβ signalling in vivo. Under steady state, S4-RII double-knockout mice had comparable, if not slightly higher, percentages of T H 17 cells than wild-type mice, while virtually no T H 17 cells were detected in Cd4-cre;Tgfbr2 fl/fl (RII knockout) mice (Extended Data Fig. 1b) . We then addressed whether S4-RII double-knockout T cells could differentiate into T H 17 cells during development of experimental autoimmune encephalomyelitis (EAE). S4-RII doubleknockout T cells differentiated into T H 17 cells as effectively as wild-type T cells (Fig. 1e) upon elicitation of EAE. S4-RII double-knockout mice developed EAE and associated pathology (Fig. 1f, g ). In addition, by using a tamoxifen-inducible Cre recombinase and oestrogen receptor (Cre-ER) fusion system 16 , we found that acute deletion of SMAD4 enabled T H 17 cell differentiation in the absence of TGFβ RII, although TGFβ RII-deficient T cells failed to differentiate into T H 17 cells under the same conditions (Fig. 1h) . These findings therefore demonstrate that SMAD4-deficient T cells can differentiate into pathological T H 17 cells in the absence of TGFβ signalling.
We next investigated how SMAD4 deletion affected the molecular program controlling T H 17 cell differentiation. The expression of many T H 17-related genes was markedly increased in SMAD4-deficient T cells compared with wild-type T cells, as early as 1 day after activation when only IL-6 was provided (Extended Data Fig. 2a) . To identify the primary target of SMAD4 for T H 17 cell differentiation, we compared gene expression in wild-type and SMAD4-deficent T cells at very early time points. Whereas the expression of many T H 17-related genes was undetectable or showed insignificant difference between wild-type and SMAD4-deficient T cells, Rorc expression was prominently increased in SMAD4-deficient T cells within 12 h of activation in the presence of IL-6 and TGFβ R inhibitor ( Fig. 2a and Extended Data Fig. 2b, c) . Such an elevated Rorc expression was similarly observed in S4-RII double-knockout T cells (Extended Data Fig. 2d ). RORγ t protein expression was consistent with Rorc mRNA expression in both S4 knockout and S4-RII double-knockout T cells (Extended Data Fig. 2e, f) . These results strongly suggest an involvement of RORγ t in SMAD4-controlled T H 17 cell differentiation. Indeed, deletion of RORγ t in SMAD4-deficient T cells abolished their T H 17 cell differentiation in the absence of TGFβ signalling (Fig. 2b) .
We then addressed whether adding back SMAD4 into SMAD4-deficient T cells could restore their function to that of wild-type cells. Indeed, retrovirus-mediated ectopic SMAD4 expression inhibited the 
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T H 17 cell differentiation of SMAD4-deficient T cells in the absence of TGFβ signalling (Fig. 2c, d ). SMAD4 suppressed the expression of Rorc before other T H 17-related genes (Fig. 2e) . In addition, Rorc was a functionally critical SMAD4 target because ectopic RORγ t expression overcame SMAD4-suppressed T H 17 cell differentiation in the absence of TGFβ signalling (Fig. 2f) . SMAD4 seemed to suppress T H 17 cell differentiation directly by influencing Rorc expression, because SMAD4 bound to multiple sites in the Rorc locus, including the promoter region ( Fig. 2g and Extended Data Fig. 2g ), but not to Il17a or Il17f loci (Extended Data Fig. 2h ).
On the basis of the findings described above, one may further predict that ectopic SMAD4 expression will also suppress RORγ t expression and T H 17 cell differentiation in the presence of both IL-6 and TGFβ (the classic T H 17 cell polarizing condition). On the contrary, however, addition of TGFβ abolished the ability of SMAD4 to suppress T H 17 cell differentiation (Fig. 3a) . The findings suggest that one important mechanism through which TGFβ enables T H 17 cell differentiation is reversing SMAD4-mediated suppression. TGFβ may do so by dislodging SMAD4 from the Rorc locus. However, this was not the case: SMAD4 remained bound to the Rorc locus regardless of the presence of TGFβ (Fig. 3b) . Another possibility is that TGFβ signalling alters the interaction of SMAD4 with other proteins, because associating with different factors is important for SMAD4 function 17 . We developed a screening strategy based on quantitative proteomics 18 (Extended Data Fig. 3a ) to identify proteins that preferentially bound to SMAD4 in the absence, but not in the presence, of TGFβ signalling in activated T cells. SKI, a factor whose deregulation is closely associated with tumorigenesis, 1p36 deletion syndrome, and Shprintzen-Goldberg syndrome [19] [20] [21] , was identified by this approach. Such a differential interaction between SMAD4 and SKI was validated by immunoprecipitation assays (Fig. 3c) . SKI is degraded upon TGFβ signalling in cancer cells 22 . Similarly, in T cells, very low doses of TGFβ stimulation during T H 17 cell differentiation induced a marked SKI protein downregulation that was partly Smad2-and Smad3-dependent ( Fig. 3d and Extended Data Fig. 3b-d) , associated with a much shortened SKI half-life (Fig. 3e) . We then investigated whether SKI-SMAD4 interaction is important for SMAD4-mediated suppression of T H 17 cell differentiation. Indeed, SMAD4 mutants 23 that are defective in interacting with SKI failed to suppress T H 17 cell differentiation of SMAD4-deficient T cells in the absence of TGFβ signalling (Fig. 3f, g ). cord-infiltrating cells (FITC, fluorescein isothiocyanate) (e) and clinical scores (f) of EAE-inflicted mice (n = 12 each group, mean ± s.e.m.), and representative pathology (g; n = 3 experiments; scale bars, 500 μ m). h, Flow cytometry of spinal-cord-infiltrating, transferred cells in EAE mice (n = 6 each group). (NS, not significant; * P < 0.05, * * P < 0.01, * * * P < 0.001; two-sided t-test; centres indicate mean values.)
These findings prompted us to test how SKI expression affects T H 17 cell differentiation. SKI was ectopically expressed to maintain its expression in the presence of both IL-6 and TGFβ . SKI expression strongly suppressed T H 17 cell differentiation (Fig. 4a) with a prompt suppression of Rorc expression in vitro (Fig. 4b) . Similarly, in vivo, T cells that ectopically expressed SKI were defective in differentiating into T H 17 cells during development of EAE (Fig. 4c) . In addition, disruption of SKI expression enabled CD4 + T cells to differentiate into T H 17 cells in the absence of TGFβ signalling (Extended Data  Fig. 4a ). These findings suggest that SKI functions downstream of TGFβ to inhibit Rorc expression and T H 17 cell differentiation. Indeed, ectopic RORγ t expression restored the T H 17 cell differentiation of SKIexpressing cells (Extended Data Fig. 4b ). SMAD4 is critical for mediating SKI function, as demonstrated by ectopic SKI expression failing to suppress the T H 17 cell differentiation of cells that were SMAD4-deficient (Fig. 4d) . Therefore, SKI and SMAD4 interact and cooperate to suppress Rorc expression and to restrain T H 17 cell differentiation.
We further investigated the mechanism through which the SKI-SMAD4 axis suppresses Rorc expression. Because SKI recruits histone deacetylases to repress gene expression 24 , we studied how the SKI-SMAD4 axis may regulate the histone acetylation of the Rorc locus. As expected, H3K9 acetylation in the Rorc promoter region was substantially elevated under T H 17 cell polarizing conditions in a TGFβ -dependent manner in wild-type T cells (Fig. 4e) . Nonetheless, SMAD4 deletion led to H3K9 acetylation of the Rorc promoter region in the absence of TGFβ signalling (Fig. 4e) . Importantly, ectopic SKI expression suppressed the acetylation of H3K9 in the Rorc promoter region in wild-type but not in SMAD4-deficient T cells (Fig. 4f) . In addition, we found that SKI bound to the Rorc promoter at the same site as SMAD4 in a SMAD4-and TGFβ -dependent manner (Extended Data Fig. 4c ). These findings suggest that the SKI-SMAD4 complex regulates the histone acetylation of the Rorc locus directly to suppress RORγ t expression.
These findings collectively suggest that, in the absence of TGFβ signalling, the SKI-SMAD4 complex binds to and modifies the histone acetylation/deacetylation of the Rorc locus to repress RORγ t expression. Yet, TGFβ stimulation leads to SKI degradation, which in turn reverses the SKI-SMAD4-mediated suppression of Rorc expression and enables T H 17 cell differentiation (Extended Data  Fig. 5 ). Because TGFβ superfamily members share many common signalling pathways, we tested whether other family members can also promote SKI degradation and T H 17 cell differentiation. We found that activin, a cytokine that activates signalling pathways similar to those activated by TGFβ 25 , induced SKI degradation in activated T cells (Fig. 4g ) and promoted T H 17 cell differentiation (Fig. 4h) . Importantly, ectopic SKI expression strongly Letter reSeArCH suppressed activin-promoted T H 17 cell differentiation (Fig. 4i ). In addition, SMAD4 was required for SKI-mediated suppression of T H 17 cell differentiation induced by activin (Fig. 4j) . Therefore, SKI-SMAD4 complexes relay diverse upstream signals to regulate T H 17 cell differentiation.
Given the vital roles for T H 17 cells in normal physiology and in many diseases, it is important to understand how these cells are generated.
IL-6 and TGFβ signalling are both instrumental in the induction of T H 17 cells 6, 7 . Although IL-6/STAT3 signalling potentiates RORγ t expression [26] [27] [28] , it is insufficient for T H 17 cell differentiation; TGFβ signalling is also required 6, 7 . In the current study, we have revealed SKI as a T H 17 suppressor whose function relies on SMAD4 to restrain RORγ t expression. Importantly, we have discovered that a central function of TGFβ in T H 17 cell differentiation is to degrade SKI, thereby Letter reSeArCH reversing SKI-SMAD4-mediated Rorc expression and enabling T H 17 cell differentiation. These findings not only shed light on how T H 17 cell differentiation is controlled, but also uncover the SKI-SMAD4 axis as a critical molecular target that interferes with T H 17 cell function for treating related immune diseases.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 29 and CD45.1 congenic wild-type mice were on the C57BL/6 background. Littermates were used unless stated otherwise. All mice were housed and bred in specific pathogen-free conditions in the animal facility at the University of North Carolina at Chapel Hill. All mouse experiments were approved by the Institution Animal Care and Use Committee of the University of North Carolina. We complied with all relevant ethical regulations. Flow cytometry and cell sorting. Lymphocytes were isolated from various organs of 6-to 18-week-old, age-and sex-matched mice. Fluorescence-conjugated anti-CD4 (GK1.5), anti-CD25 (PC61.5), anti-CD62L (MEL-14), anti-CD44 (IM7), anti-CD45.1 (A20), anti-CD45.2 (104), anti-IFNγ (XMG1.2), anti-Thy1.1 (OX-7), and anti-IL-17A (TC11-18H10.1) (Biolegend) were used. For intracellular cytokine staining, lymphocytes were stimulated for 4 h with 50 ng ml −1 of PMA (phorbol 12-myristate 13-acetate) and 1 μ M ionomycin in the presence of brefeldin A. Stained cells were analysed on a FACSCanto (BD Biosciences) or were sorted on a MoFlo (DakoCytomation, Beckman Coulter). A figure exemplifying the gating strategy is provided in Supplementary Fig. 2 T-cell culture and differentiation. Naive (CD4
) T cells were sorted from the peripheral lymph nodes and spleens of mice. Cells were then activated either in plates coated with 10 μ g ml −1 anti-CD3 (145-2C11, BioXCell) and 10 μ g ml −1 anti-CD28 (37.51, BioXCell) or by soluble 1 μ g ml −1 anti-CD3 and irradiated (3,000 cGy) T-cell-depleted splenocytes. Cells were cultured in RPMI medium with 10% FBS and 1% antibiotics unless specifically indicated. Cells were cultured in the presence of 20 μ g ml −1 anti-IFN-γ (XMG1.2, BioXcell) and 20 μ g ml −1 anti-IL-4 (11B11, BioXcell). For the IL-6 + TGFβ condition, cells were cultured in the presence of 40 ng ml −1 recombinant IL-6, 1 ng ml −1 TGFβ 1 (R&D systems), 20 μ g ml −1 anti-IFN-γ , and 20 μ g ml −1 anti-IL-4. For the IL-6 condition, cells were cultured in the presence of 40 ng ml −1 recombinant IL-6, 20 μ g ml
anti-IFN-γ , and 20 μ g ml −1 anti-IL-4. Recombinant human activin A (100 ng ml −1 ; Biolegend) was used in the indicated conditions. TGFβ R inhibitor SB525334 (10 μ M; Selleckchem) was added into the culture medium with the indication 'i' .
For retroviral transduction, CD4
+ T cells were isolated and cultured under various conditions on day 0 and then spin inoculated with indicated retroviruses at 1,500g at 30 °C for 1.5 h on day 1. Cells were harvested and analysed by flow cytometry on day 4 unless stated otherwise in the figure legends. Elicitation of EAE in mice. MOG peptide (50 μ g) and CFA were emulsified and subcutaneously injected into mice on day 0. Pertussis toxin (200 ng) was intraperitoneally injected on day 0 and day 2. Mice were monitored and euthanized at appropriate times. The EAE clinical scores were recorded on the basis of the following criteria: 1, limp tail; 2, poor righting ability and/or partial hind-limb paralysis; 3, total hind-limb paralysis; 4, hind-limb paralysis + 75% of body paralysis; 5, moribund; 6, dead. Seventeen to 18 days after EAE induction, diseased mice were euthanized and the spinal cords were subjected to pathological analysis using Luxol fast blue staining. Lesions were indicated by the arrows in the figures. T cells from spinal cords were collected and subjected to immunological analysis. For EAE experiments with T-cell adoptive transfer, CD4 + T cells of different genotypes or transduced with indicated retrovirus were transferred into Rag1 −/− or irradiated wild-type recipient mice on day − 1. EAE was then elicited in the recipient mice on day 0. Tamoxifen was injected into the recipient mice on day 2 and day 4 to delete floxed alleles in Cre-ER-expressing T cells. Spinal cord lymphocytes were isolated and transferred cells were analysed by flow cytometry on day 17 after EAE elicitation. Immunoblotting, immunoprecipitation, and mass spectrometry. For immunoblotting, protein extracts were resolved by AnyKD SDS-PAGE gel (Bio-Rad), transferred to a polyvinylidene fluoride membrane (Millipore), and analysed by immunoblotting with the following antibodies: anti-SKI (H-329, Santa Cruz), anti-RORγ t (B2D, Santa Cruz), anti-SMAD4 (D3M6U, CST), anti-pSmad3 (C25A9, CST), and anti-β -actin (I-19, Santa Cruz). For gel source data, see Supplementary Fig. 1 For immunoprecipitation analysis, cells were lysed with extract buffer (20 mM HEPES, pH 7.9, with 1.5 mM MgCl 2 , 0.42 M NaCl, 0.2 mM EDTA, and 25% (v/v) glycerol, 1% Triton X-100) containing protease inhibitor mixture (Roche Applied Science), diluted with three volumes of dilution buffer (20 mM HEPES, pH 7.9, with 1.5 mM MgCl 2 , 0.2 mM EDTA, 10 mM KCl, and 25% (v/v) glycerol) and sonicated with Bioruptor PICO. The supernatant was incubated with magnetic beads (Bio-Rad) that had been conjugated with indicated antibody or anti-Flag M2 magnetic beads (Sigma) in a cold room overnight. The immunocomplex was washed six times with washing buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 0.2 mM EDTA, and 150 mM NaCl) containing 0.1% NP40. Associated proteins were eluted by adding 2× Laemmli sample buffer (Bio-Rad) and incubated at 95 °C for 5 min. The eluted proteins were resolved by SDS-PAGE gel for subsequence immunoblotting or mass spectrometry.
For MS analysis, CD4
+ T cells were cultured in SILAC/AACT L media (RPMI1640 media depletion of lysine and arginine were supplemented with normal l-lysine (K0)/l-arginine(R0)), or SILAC/AACT H media (RPMI1640 media depletion of lysine and arginine were supplemented with 13 C 6 15 N 2 -lysine (K8)/ 13 C 6 15 N 4 -arginine (R10)). After immunoprecipitation, eluted proteins were resolved in SDS-PAGE gel and subjected to in-gel digestion with trypsin (Promega) at 37 °C. Mass spectrometry analyses of the immunoprecipitation products were performed on a LTQ Orbitrap Velos (Thermo Scientific) coupled with a nano-LC-Ultra system (Eksigent). Samples were re-suspended in 20 μ l HPLC buffer A (0.1% formic acid in water) and 5 μ l was loaded onto an IntegraFrit column (C18, New Objective). The peptides were eluted at a flow rate of 250 nl min −1 with a multi-step gradient, 5-40% buffer B (0.1% formic acid in acetonitrile) for 70 min, 40-80% buffer B for 5 min, 80% buffer B for 5 min, 80-5% buffer B for 5 min, and 5% buffer B for 5 min. The mass spectrometry spectra were acquired in a data-dependent and positive ion mode at a spray voltage of 2.1 kV by XCalibur software (version 2.1, Thermo Scientific). Orbitrap analyser was used to do the survey scan at a resolution of 60,000 and a mass range between m/z 350 and 1,800. The top 11 most intense ions in every cycle were subjected to collision-induced dissociation fragmentation in the LTQ Orbitrap with normalized collision energy at 35% and activation Q 0.25. Dynamic exclusion was enabled. Mass spectrometry raw files were analysed by MaxQuant (version 1.5.0.25). They were searched with Andromeda against the Uniprot mouse database (release date 30 November 2010; 20,248 entries). A database containing contamination proteins was also used to exclude peptides that matched this database. Searches were performed with a precursor ion mass tolerance of 7.5 p.p.m. and tandem mass spectrometry tolerance at 0.5 Da. Peptide and protein identifications were filtered to a maximum 1% and 5% false discovery rate, respectively. Up to two missed cleavages were allowed. Only peptides with a minimum length of seven amino acids were considered for identification. The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD007172. ChIP assay. The ChIP assay was done according to the protocol of Upstate Biotechnology. Cells were cross-linked with 1% formaldehyde and lysed in lysis buffer. Lysates were sonicated with Bioruptor PICO or Covaris S220 to shear genomic DNA. Chromatin was subjected to immunoprecipitation overnight at 4 °C with anti-H3K9ac (ab4441, Abcam), anti-IgG (sc-2027, Santa Cruz), anti-SMAD4 (EP618Y, Abcam), or anti-SKI (H-329, Santa Cruz). Quantitative real-time PCR was performed to determine the relative abundance of target genomic DNA. Specific PCR primers to detect Rorc promoter were GGGGAGAGCTTTGTGCAGAT and AGTAGGGTAGCCCAGGACAG. ChIP-seq. The sequencing libraries were prepared by a NEXTflex Rapid DNaseq kit (Bioo Scientific Corporation) and sequenced on NextSeq 500 (Illumina) at the National Institute of Environmental Health Sciences Epigenomics Core Facility. For primary data processing, data were collected using 36 paired-end reads on a NextSeq 500 platform (Illumina). Raw reads (56 million to 72 million reads per sample) were first cleaned for adaptor sequences using Trim Galore with default parameters. Cleaned reads were aligned to mm10 using Bowtie1 with the parameters -m1, -v2 and -X1500. These parameters ensured that fragments up to 1,500 base pairs (-X1500) and mismatch up to 2 (-v2) were allowed to align, and that only unique aligned reads were collected (-m1). For all data files, duplicates were removed using Picard. The ChIP-seq data are available in the Gene Expression Omnibus repository at the National Center for Biotechnology Information under accession number GSE101593. RNA-seq. Total RNA was extracted from cells by lysing with TriZol (Thermo Fisher Scientific), and purified with an RNeasy mini kit (Qiagen). RNA-seq libraries were generated and poly(A) enriched using 1 μ g of RNA as input with a TruSeq RNA Sample Prep Kit (Illumina, San Diego, California, USA).
Indexed samples were sequenced using the 50 base pair paired-end protocol via the HiSeq 2500 (Illumina) according to the manufacturer's protocol. Reads (32 million to 45 million reads per sample) were aligned to the University of California, Santa Cruz (UCSC) mm10 reference genome using STAR with default parameters. The quantification results from featureCounts were then analysed with the Bioconductor package DESeq2, which fits a negative binomial distribution to estimate technical and biological variability. A gene was considered differentially expressed if the P value for differential expression was less than 0.05. The RNAseq data are available in the Gene Expression Omnibus at the National Center for Biotechnology Information under accession number GSE101527. SKI guide RNA design for CRISPR-Cas9. Guide RNAs (gRNAs) targeting the first exon of SKI were designed by the CHOPCHOP web tool 30 . Two gRNAs of the highest score and specificity were selected on the basis of the algorithm. The sequences for the chosen gRNAs were gRNA1:GTCTTCTGCAGCCCCGGGTG and gRNA2:GCGAGCTCATGGAGCTCAGG. + T cells from wild-type and Cd4-cre;Smad4 fl/fl (S4 KO) mice were activated in the presence of IL-6 and TGFβ R inhibitor. Cells were harvested after 12 h. ChIP-seq assay was performed with SMAD4 antibody. The enrichment of SMAD4 binding to the Il17a and Il17f loci was determined by the mapped read coverage of SMAD4 ChIP-seq data. The results of two independent experiments were show as '#1' and '#2' . (* P < 0.05, * * P < 0.01, * * * P < 0.001; two-sided t-test; NS, not significant). 
Data exclusions
Describe any data exclusions. For IP-MS:A contamination protein database in Maxquant was used to exclude peptides that match this database. The parameters for database searching were set as: 1) Carbamidomathylation of cysteines was set as fixed modification and protein N-terminal acetylations as well as oxidation of methionines were set as variable modification for the peptide search; 2) A maximum mass deviation of 7.5 ppm was allowed for precursor`s identification and 0.5 Da was set as match tolerance for fragment identification (acquision in orbitrap); 3) Up to two missed cleavages was allowed for trypsin digestion; 4) Peptide length of seven amino acids was considered for protein identification and quantification; 5) The minimum member of total peptides a protein group was set to 1 and the minimum member of razor+ unique peptides was set to 1; 6) The minimum Andromeda score for accepting an MS/MS identification for modified peptides was set to 40; 7) Using unique and razor peptides for protein quantification; 8) The false discovery rates (FDR) for peptide and protein identifications were set to a maximum 1% and 5% respectively. fold change and dispersion for RNA-seq data with DESeq2." Genome Biology, 15, pp. 550), which fits a negative binomial distribution to estimate technical and biological variability.
Replication
Describe whether the experimental findings were reliably reproduced. The experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice with needed genotypes and ages were chosen randomly. For example, different group of mice (e.g. WT and KO, littermates if possible) were mixed in one cage, and treated equally without knowing the identity of the mice. The mice were then identified upon the completion of the experiments.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Samples were labeled with simple numbers. The person who performed the experiments did not know the exact samples until after data were analyzed.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study. For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No restricted material was used. c. Report whether the cell lines were tested for mycoplasma contamination.
No eukaryotic cell lines were used in the presented data.
d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used in the presented data.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Smad4fl/fl, Tgfbr2fl/fl, Cd4cre, ERCre, Rag1-/-, Rorc-/-, Cre-dependentCas9 knockin (CdC) and CD45.1 congenic wild-type mice were on the C57BL/6 background. 6-18 weeks old same sex (both males and females) mice were used. Primary T cells or HSC were isolated from the mice and then used for the subsequent experiments.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
Study did not involve human research participants
